- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02028715
Efficacy of IV Acetaminophen for Pain Management
Efficacy of IV Acetaminophen for Pain Management Following Major Gynecologic Surgery: Effect on Opioid Rescue, Return of Bowel Function, Cost and Length of Hospital Stay.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a patient-blinded prospective study in which patients that undergo major gynecologic surgery via an open abdominal approach will be randomized into two arms:
- Control Group: Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
- Experimental Group: Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
Outcomes that will be analyzed include the amount of opioids used; time to return of bowel function designated as passage of flatus; time to first bowel movement if it occurs while inpatient; duration of hospital stay; and patient symptoms and satisfaction at the 24 and 48 hour marks as well as at time of discharge.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Canton, Ohio, United States, 44720
- Aultman Health Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-Female patients undergoing major gynecologic surgery via an open abdominal approach. The included surgeries would be exploratory laparotomy with or without removal of uterus, fallopian tubes, or ovaries.
Exclusion Criteria:
- Patients with baseline preoperative liver function enzymes (AST and ALT) that are greater than twice the upper limit of normal would be excluded.
- Patients with baseline CrCl <30.
- Patients that require intensive postoperative care and delayed extubation will typically require additional sedation which would impede adequate evaluation of the two study pain regimens as they are designed to be patient controlled.
- Patients with complications unrelated to the pain regimens that prolong their stay would be excluded from the evaluation of hospital stay and cost effectiveness analyses. Examples would include but are not limited to pre-renal azotemia and acute renal failure; pneumonia; venous thromboembolism; or need for re-exploration laparotomy.
- Allergy to acetaminophen would exclude those patients set to enter the experimental IV acetaminophen study arm. One exception would be if the allergy were trivial and related to route of administration such as mild nausea with oral acetaminophen.
- Patients that undergo a bowel resection during surgery as it may adversely effect return of bowel function
- Patients that have required regular opioid intake for the 7 days preceding surgery.
- NSAIDs within 8 hours of surgery.
- Chronic steroid use with the exception of low-dose inhaled steroid formulations.
- Chronic alcohol or drug abuse.
- Patients currently pregnant.
- Patients unable to provide informed consent.
- Age >85
- Any physical, medical, and mental condition that would make participation in the study inadvisable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Experimental (Normal Saline)
Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn.
Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
|
Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Other Names:
|
|
Active Comparator: Experimental (IV Acetaminophen)
Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn.
IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
|
IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Opioid Rescue - 48 Hours
Time Frame: First 48 hours including pre-operative and intra-operative medications
|
Mean number opioid rescue in the first 48 hours calculated by converting all opiates to intravenous morphine
|
First 48 hours including pre-operative and intra-operative medications
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Return of Bowel Function
Time Frame: Duration of hospital stay (up to 7 days).
|
Time to return of bowel function (passage of flatus) in hours
|
Duration of hospital stay (up to 7 days).
|
|
Patient Satisfaction - Pain Control at 24 Hours, 48 Hours, and Discharge
Time Frame: At 24 hours 48 hours, and discharge (up to 7 days)
|
Subjects will rate their overall satisfaction with pain control on a 5-point Likert scale: 1=Strongly disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree
|
At 24 hours 48 hours, and discharge (up to 7 days)
|
|
Patient Satisfaction - Nausea Control at 24 Hours, 48 Hours, and Discharge
Time Frame: At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
Subjects will rate their overall satisfaction with nausea control on a 5-point Likert scale 1=Strongly disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree
|
At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
|
Patient Satisfaction - Bloating at 24 Hours, 48 Hours, and Discharge
Time Frame: At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
Subjects will rate their overall satisfaction with bloating on a 5-point likert scale 1=Strongly disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree
|
At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
|
Patient Satisfaction - Pruritis at 24 Hours, 48 Hours, and Discharge
Time Frame: At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
Subjects will rate their overall satisfaction with pruritis control on a 5-point likert scale 1=Strongly disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree
|
At 24 hours, 48 Hours, and Discharge (up to 7 days)
|
|
Length of Stay
Time Frame: Surgery to discharge
|
Mean length of post-operative stay in days
|
Surgery to discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura K Randolph, DO, MS, Aultman Health Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013.08.22.F2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-operative Pain
-
Liaquat National Hospital & Medical CollegeCompletedPain | Post-operative Pain | Post-operative Pain ControlPakistan
-
Unity Health TorontoAFP Innovation FundRecruitingSpinal Surgery | Post-operative Pain Management | Post-operative CareCanada
-
Kaohsiung Medical University Chung-Ho Memorial...Not yet recruitingPostoperative Complications | Chronic Post Operative Pain | Acute Post Operative PainTaiwan
-
MercyOne Des Moines Medical CenterTerminatedPost Operative Pain | Post Operative Nausea and VomitingUnited States
-
Ain Shams UniversityRecruiting
-
University Tunis El ManarCompletedPost-operative Pain | Post-operative AnxietyTunisia
-
E-DA HospitalNot yet recruitingCesarean Section | Post Operative Pain, Acute | Post Operative Pain, ChronicTaiwan
-
Mount Sinai Hospital, CanadaWomen's College HospitalRecruitingSurgery | Laparoscopy | Post-operative Pain | Laparoscopic | Post-operative Recovery | PenumoperitoneumCanada
-
University of HaifaRecruiting
-
Sohag UniversityNot yet recruitingPost Operative Pain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of